IMMUNOHISTOCHEMISTRY: PD-L1 CLONE 22C3 (DAKO) (J293)
₹14,870
About This Test
PD-L1 (Programmed Death Ligand 1) is expressed on tumor cells and binds with PD-1 which is expressed on immune cells. This interaction hampers the immune response against tumor cells. Drugs have been developed to block this interaction & boost the immune response. PD-L1 expression is used to guide immunotherapy decisions. Clone 22C3 is indicated as a companion diagnostic aid in identifying patients for treatment with Pembrolizumab in the following tumors : Non-small cell Lung carcinoma (NSCLC), Gastric or Gastroesophageal junction adenocarcinoma, Cervical carcinoma, Urothelial carcinoma, Head and neck squamous cell carcinoma (HNSCC) & Esophageal squamous cell carcinoma (ESCC).
At a Glance
Home Collection
Available
Report TAT
1 Day
Category
OUTSOURCE
Preparation / Prerequisite
Submit Tissue in 10% formal-saline OR formalin fixed paraffin embedded Tissue Block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Test Parameters 1
View All 1 Parameters
- IMMUNOHISTOCHEMISTRY: PD-L1 CLONE 22C3 (DAKO)
Frequently Asked Questions
1. What Is outsourced test ?
Outsourced test are being done from Dr. Lal Path Lab. Charges and reporting time is same as of Dr. Lal Path Labs.
2. Any Preparation for the test ?
Provide a copy of the Histopathology report.
3. Why this test is important ?
PD-L1 (Programmed Death-Ligand 1) is a protein expressed on the surface of some tumor cells and immune cells. It interacts with PD-1 receptors on T-cells to inhibit immune response, allowing cancer cells to evade the immune system. The 22C3 clone (Dako) is a widely used antibody for testing PD-L1 expression in tumors to guide immunotherapy decisions.
TAT Policy
The Turnaround Time (TAT) depends on the following factors:
- Registration date and time
- Type of scan or test
- Scan time or sample collection time
In uncommon circumstances, TAT may be delayed due to test complexity or reasons beyond our control. You will be informed of the estimated TAT at the time of registration.
